Showing: 1 - 9 of 9 RESULTS
Briefing News Psilocybin Psychedelics Revive Therapeutics

Revive Therapeutics Provides Update On Current Psilocybin Programs

Revive Therapeutics (CSE: RVV) this morning provided a corporate update as it pertains to its psychedelic assets. The update primarily focused on the current status of the firms various psychedelics-related development and clinical programs, which largely surround the use of psilocybin. The company currently has a number of ongoing studies as they relate to the …

Briefing Compass Pathways Psilocybin Psychedelics

Compass Pathways Closes Enrollment For Phase IIb Psilocybin Clinical Trial

Compass Pathways (NASDAQ: CMPS) this morning provided a brief update to the market on the latest status of its ongoing phase IIb psilocybin therapy trial. The trials are being conducted to test the efficacy of psilocybin against treatment-resistant depression. A total of 216 patients have now completed the administration of psilocybin under the clinical trial, …

Briefing Numinus Wellness Inc Psilocybin Psychedelics

Numinus Wellness To Undertake Phase 1 Study Of Psilocybin Extract

Numinus Wellness (TSXV: NUMI) is undertaking further studies of its psilocybin products. The company this morning announced a partnership with KGK Science, whereby it will begin studying a psilocybin extract produced in its lab. The clinical trial is to study the safety and psychoactive properties of a Psilocybe mushroom product that has been extracted and …

Briefing News Psilocybin Psychedelics Revive Therapeutics

Revive Therapeutics Files For Patent On Oral Thin Film With Psilocybin

Revive Therapeutics (CSE: RVV) this morning announced that it has successfully completed research on an oral thin film delivery system with psilocybin, as well as filed for a related provisional patent for the technology with the US Patent and Trademark office. The thin film technology with developed under a research partnership with the Reed Research …

Briefing News Pharmather Psilocybin Psychedelics Revive Therapeutics

Revive Therapeutics Enters LOI To Acquire Psilocybin Program From PharmaTher

Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a letter of intent to acquire PharmaTher Inc’s (CSE: PHRM) psilocybin program. The proposed acquisition is to consist of a number of intellectual property-related assets to PharmaTher’s psilocybin research. The letter of intent follows the previous announcement between the two firms that they …

Briefing News Psilocybin Psychedelics Revive Therapeutics

Revive Therapeutics Completes Psilocybin Oral Thin Film Strip Product

Revive Therapeutics (CSE: RVV) has completed its oral thin film strip product for psilocybin after several months of prototyping. The company made the announcement this morning that the product, developed via a research partnership with Reed Research Group from the University of Wisconsin-Madison, has been completed with several dosage ranges available. The oral thin film …

Briefing Magic Mushrooms Psilocybin Psychedelics Revive Therapeutics

Shroom Boom! Has Michael Frank Brought Revive Back from the Dead?

Yesterday Revive Therapeutics (CSE: RVV) increased 81.8% from 5.5c to 10c on 4.1M shares traded. Presumably, RVV is beginning to take notice, thanks to the listing of other psilocybin issuers in Canada including MindMed (NEO: MMED) and Champignon Brands (CSE: SHRM). Prior to the recent run up, it has been a challenging couple of years …

Briefing Cannabis Full Analysis Harvest Moon Research Psilocybin Psychedelics

Parallels of Psychedelic Mushrooms and Cannabis

Psychedelics are a class of pharmacological compounds that produce unique and profound changes of consciousness. The most common psychedelics are psilocybin, LSD (lysergic acid diethylamide), DMT (dimethyltryptamine), and mescaline. In the past year, psilocybin has seen a reemergence. Decriminalization efforts are underway throughout the US. Mainstream media have begun to run specials on its popularity. …